Breast Disease pp 585-589 | Cite as

Management of Malignant Pleural Effusions in Breast Cancer

  • Jelena Grusina Uyumaz
  • Tugba Cosgun
  • Alper TokerEmail author


Carcinomatous pleurisy is often a manifestation of malignant disease and an indicator of the terminal stage of disease. Breast carcinoma is one of the most common neoplasms and causes approximately one third of all malignant pleural effusions (MPE). The ideal treatment is to remove the fluid and prevent its re-accumulation. Various methods, such as thoracentesis, chest tube drainage, permanent catheter placement, talc or other adhesive molecule uses, and video-assisted thoracoscopic surgery (VATS), have been used to create pleural symphysis. Repeated thoracentesis controls less than 15% of the effusions. A tunneled indwelling pleural catheter (TIPC) may improve symptoms for patients with MPE and does not appear to be associated with major complications; additionally, this method does not require hospitalization. TIPC also prevents the pain and complications that are associated with chemical agents. Pleurodesis with VATS has very high efficacy in terms of effusion control if preoperative indications (complete pulmonary expansion) are respected. The advantage of pleurodesis with VATS is the possibility of conducting the procedure in direct view and achieving uniform talc distribution, even in the most inaccessible areas. Bedside talc pleurodesis has a high success rate when thoracoscopy is unavailable.


Breast carcinoma Thoracentesis Chest tube drainage Permanent catheters Talc poudrage Pleurodesis Thoracoscopy Re-accumulation Lung re-expansion Trapped lung Talc pleurodesis Sclerosing agent Doxycycline pleurodesis Bleomycin Erythromycin c-ErbB-2 (a type of receptor tyrosine kinase) Malignant pleural effusions (MPE) Video-assisted thoracoscopic surgery (VATS) Tunneled indwelling pleural catheter (TIPC) 


  1. 1.
    Arellano-Orden E, Romero-Romero B, Sanchez-Lopez V, Martin-Juan J, Rodriguez-Panadero F, Otero-Candelera R. Survivin is a negative prognostic factor in malignant pleural effusion. Eur J Clin Investig. 2018;48(4): Scholar
  2. 2.
    Schrijver WAME, Schuurman K, van Rossum A, Dutch Distant Breast Cancer Metastases Consortium, Peeters T, Ter Hoeve N, Zwart W, van Diest PJ, Moelans CB. Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. Oncotarget. 2017;8(33):55550–61.CrossRefGoogle Scholar
  3. 3.
    Putnam JB Jr. Malignant pleural effusions. Surg Clin North Am. 2002;82:867–83.CrossRefGoogle Scholar
  4. 4.
    Perrone F, Carlomagno C, De Placido S. First-line systemic therapy for metastatic breast cancer and management of pleural effusion. Ann Oncol. 1995;6:1033–43.CrossRefGoogle Scholar
  5. 5.
    Raju R, Kardinal C. Pleural effusion in breast carcinoma: analysis of 122 cases. Cancer. 1981;48:2524–7.CrossRefGoogle Scholar
  6. 6.
    Fentiman IS, Millis R, Sexton S, Hayward JL. Pleural effusion in breast cancer. A review of 105 cases. Cancer. 1981;47:2087–92.CrossRefGoogle Scholar
  7. 7.
    Santos GT, Prolla JC, Camillo ND, Zavalhia LS, Ranzi AD, Bica CG. Clinical and pathological factors influencing the survival of breast cancer patients with malignant pleural effusion. J Bras Pneumol. 2012;38(4):487–93.CrossRefGoogle Scholar
  8. 8.
    Sahn SA. Management of malignant pleural effusions. Monaldi Arch Chest Dis. 2011;56:394–9.Google Scholar
  9. 9.
    Anderson CB, Philpott GW, Ferguson TB. The treatment of malignant pleural effusion. Cancer. 1974;33:916–22.CrossRefGoogle Scholar
  10. 10.
    Hirata T, Yonemori K, Hirakawa A, Shimizu C, Tamura K, Ando M. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients. Eur Respir J. 2011;38(6):1425–30.CrossRefGoogle Scholar
  11. 11.
    Reshad K, Inui K, Takahashi Y, Hitomi S. Treatment of malignant pleural effusion. Chest. 1985;88:392–7.CrossRefGoogle Scholar
  12. 12.
    Bielsa S, Hernandez P, Rodriguez-Panadero F, Taberner T, Salud A, Porcel JM. Tumor type influences the effectiveness of pleurodesis in malignant effusions. Lung. 2011;189(2):151–5.CrossRefGoogle Scholar
  13. 13.
    Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26(1):70–6.CrossRefGoogle Scholar
  14. 14.
    Putnam JB Jr, Light RW, Rodriguez RM, Ponn R, Olak J, Pollak JS. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusion. Cancer. 1999;86:1992–9.CrossRefGoogle Scholar
  15. 15.
    Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129(2):362–8.CrossRefGoogle Scholar
  16. 16.
    Spector M, Pollak JS. Management of malignant pleural effusions. Semin Respir Crit Care Med. 2008;29(4):405–13.CrossRefGoogle Scholar
  17. 17.
    Warren WH, Kim AW, Liptav MJ. Identification of clinical factors predicting Pleurx catheter removal in patients treated for malignant pleural effusion. Eur J Cardiothorac Surg. 2008;33(1):89–94.CrossRefGoogle Scholar
  18. 18.
    Ohm C, Park D, Vogen M, Bendick P, Welsh R, Pursel S, Chmielevski G. Use of an indwelling pleural catheter compared with thoracoscopic talc pleurodesis in the management of malignant pleural effusions. Am Surg. 2003;69(3):198–202.PubMedGoogle Scholar
  19. 19.
    Demmy TL, Gu L, Burkhalter JE, Toloza EM, D’Amico TA, Sutherland S. Optimal management of malignant pleural effusions (results of CALGB 30102). J Natl Compr Cancer Netw. 2012;10(8):975–82.CrossRefGoogle Scholar
  20. 20.
    Sioris T, Sihvo E, Salo J, Räsänen J, Knuuttila A. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis. Eur J Surg Oncol. 2009;35(5):546–51.CrossRefGoogle Scholar
  21. 21.
    Thomas R, ETH F, Smith NA, Lee P, BCH K, Yap E, Horwood FC, Piccolo F, DCL L, Garske LA, Shrestha R, Kosky C, Read CA, Murray K, YCG L. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial. JAMA. 2017;318(19):1903–12.CrossRefGoogle Scholar
  22. 22.
    Demirhan O, Ordu C, Toker A. Prolonged pleural catheters in the management of pleural effusion due to breast cancer. J Thorac Dis. 2014;6(2):74–8.PubMedPubMedCentralGoogle Scholar
  23. 23.
    De Campos JR, Vargas FS, De Campos Werebe E, Cardoso P, Teixeira LR, Jatene FB. Thoracoscopy talc poudrage: a 15-year experience. Chest. 2001;119:801–6.CrossRefGoogle Scholar
  24. 24.
    Cardillo G, Facciolo F, Carbone L, Regal M, Corzani F, Ricci A. Long-term follow up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg. 2002;21:302–5.CrossRefGoogle Scholar
  25. 25.
    Pearson FG, MacGregor DC. Talc poudrage for malignant pleural effusion. J Thorac Cardiovasc Surg. 1996;51:732–8.Google Scholar
  26. 26.
    Viallat JR, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest. 1996;110:1387–93.CrossRefGoogle Scholar
  27. 27.
    Kuzniar TJ, Blum MG, Kasibowska -Kuzniar K, Mutlu GM. Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis. Ann Thorac Surg. 2006;82:1976–81.CrossRefGoogle Scholar
  28. 28.
    Ferrer J, Montes JF, Villarino MA, Light RW, Garcia Valero J. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest. 2002;122:1018–27.CrossRefGoogle Scholar
  29. 29.
    Antunes G, Neville E, Duffy J. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58(Suppl II):ii29–38.CrossRefGoogle Scholar
  30. 30.
    Sedrakyan A, Browne J, Swift S, Tan C. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29(5):829–38.CrossRefGoogle Scholar
  31. 31.
    Balassoulis G, Sichletidis L, Spyratos D, Chloros D, Zarogoulidis K, Kontakiotis T. Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol. 2008;31(4):384–9.CrossRefGoogle Scholar
  32. 32.
    Light RW. New agents for pleurodesis. Curr Resp Care Rep. 2013;2(2):88–92.CrossRefGoogle Scholar
  33. 33.
    Terra RM, Kim SY, Pego-Fernandes PM, Teixeira LR, Vargas FS, Jatene FB. Is silver nitrate pleurodesis for patients with malignant pleural effusion feasible and safe when performed in an outpatient setting? Ann Surg Oncol. 2011;18(4):1145–50.CrossRefGoogle Scholar
  34. 34.
    Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy. Respirology. 2006;11(1):105–8.CrossRefGoogle Scholar
  35. 35.
    Bagheri R, Noori M, Rajayi M, Attaran D, Hashem M, Asna Ashari A, Mohammadzadeh Lari S, Basiri R, Rezaeetalab F, Afghani R, Salehi M. The effect of iodopovidone versus bleomycin in chemical pleurodesis. Asian Cardiovasc Thorac Ann. 2018;1:218492318778485.Google Scholar
  36. 36.
    Perikleous P, Waller DA. Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases. J Visc Surg. 2017;22(3):85.CrossRefGoogle Scholar
  37. 37.
    Colleoni M, Minchella I, Mazzarol G, Nolè F, Peruzzotti G, Rocca A. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol. 2000;11:1057–9.CrossRefGoogle Scholar
  38. 38.
    Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer. Anticancer Res. 2003;23:4443–9.PubMedGoogle Scholar
  39. 39.
    Gasparri R, Leo F, Veronessi G, De Pas T, Colleoni M, Maisonneuve P, Pelosi G. Video-assisted management of malignant pleural effusion in breast carcinoma. Cancer. 2006;106:271–6.CrossRefGoogle Scholar
  40. 40.
    Hunt BM, Farivar AS, Vallières E, Louie BE, Aye RW, Flores EE, Gorden JA. Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Ann Thorac Surg. 2012;94(4):1053–7.CrossRefGoogle Scholar
  41. 41.
    Bhatnagar R, Keenan EK, Morley AJ. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med. 2018;378(14):1313–22.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Jelena Grusina Uyumaz
    • 1
  • Tugba Cosgun
    • 2
  • Alper Toker
    • 3
    • 4
    Email author
  1. 1.Department of Thoracic SurgeryGaziosmanpasa Taksim Education and Research HospitalIstanbulTurkey
  2. 2.Department of Thoracic SurgeryIstanbul Bilim UniversityIstanbulTurkey
  3. 3.Department of Thoracic SurgeryGroup Florence Nightingale HospitalsIstanbulTurkey
  4. 4.Department of Thoracic SurgeryIstanbul Medical School, Istanbul UniversityIstanbulTurkey

Personalised recommendations